Watch the latest episode:
A brutal Friday on Wall Street had investors asking whether the tech sell-off was a sneak preview of a market meltdown. On Switzer TV this week, Peter Switzer put that question to Raymond Chan of Morgans and Jacqui Fearnley of ArcPoint OCIO, then met Daniel Tillett, the chief executive of ASX-listed Racura Oncology.
Read all the tips from this week’s Switzer TV in All the stock tips from this week on Switzer TV (9 June 2026) on the Switzer Report.
Here’s a taste of what each guest brought to the show.
- Raymond Chan, Morgans: whether Friday’s rout was the start of something darker, and the beaten-up names he would buy anyway, including one of the market’s most disappointing floats.
- Jacqui Fernley, ArcPoint OCIO: why she is staying risk-on, the trillion-dollar force she says is driving the US market, and her warning on the SpaceX float.
- Daniel Tillett, Racura Oncology: the Australian biotech that says it has cracked a cancer target left untouched for 40 years, and why its shareholders keep backing it.
This article does not take into account the investment objectives, financial situation or particular needs of any individual. It does not constitute formal advice. Consider the appropriateness of the information in regards to your circumstances. Before acting on anything we discuss, we strongly recommend you seek the appropriate professional advice. Stocks mentioned are referenced as representative of declared business exposure to the sectors discussed, not as recommendations.
